News Eisai angry over thyroid cancer drug impasse in England Thyroid cancer drug falls through gap in NHS funding
News England's new-look Cancer Drugs Fund begins But concerns remain about access to oncology medicines.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
News Patients denied thyroid cancer drug in England Eisai considers legal action over funding "black hole".
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.